利拉鲁肽对伴或不伴心力衰竭的糖尿病患者心血管结局的影响
LEADER试验事后分析纳入9340例T2D高心血管风险患者,按基线心衰史(NYHA I-III级)分层。利拉鲁肽对主要复合心血管事件、死亡及心衰住院的影响在伴与不伴心衰患者中一致,交互作用均不显著。提示利拉鲁肽可用于伴或不伴NYHA I-III级心衰史的T2D患者。
要点
- 利拉鲁肽对主要心血管事件的影响在伴与不伴心衰史患者中一致(交互P=0.53)。
- 利拉鲁肽未增加心衰住院风险,无论有无心衰史(交互P=0.22)。
- 利拉鲁肽可用于伴或不伴NYHA I-III级心衰史的T2D高心血管风险患者。
核心结论
- 利拉鲁肽对主要心血管事件、死亡及心衰住院的影响在伴与不伴NYHA I-III级心衰史的T2D患者中一致。
- 基于此,利拉鲁肽应考虑适用于伴或不伴NYHA I-III级心衰史的T2D患者。
研究设计与样本
- LEADER为多国、双盲、随机试验,纳入9340例T2D高心血管风险患者,1:1分配至利拉鲁肽(每日1.8 mg或最大耐受剂量至1.8 mg)或安慰剂加标准治疗,随访3.5至5年。
- 本次为事后Cox回归分析,按基线心衰史分层;NYHA IV级心衰为排除标准。
主要发现
- 基线时18%患者有NYHA I-III级心衰史(利拉鲁肽组835/4668,安慰剂组832/4672)。
- 主要不良心血管事件:伴心衰史HR 0.81(95%CI 0.65-1.02),不伴心衰史HR 0.88(95%CI 0.78-1.00),交互P=0.53。
- 死亡:伴心衰史HR 0.89(95%CI 0.70-1.14),不伴心衰史HR 0.83(95%CI 0.70-0.97),交互P=0.63。
- 心衰住院:伴心衰史HR 0.98(95%CI 0.75-1.28),不伴心衰史HR 0.78(95%CI 0.61-1.00),交互P=0.22。
- 心衰住院或心血管死亡复合:伴心衰史HR 0.92(95%CI 0.74-1.15),不伴心衰史HR 0.77(95%CI 0.65-0.91),交互P=0.19。
临床怎么用
- 对伴或不伴NYHA I-III级心衰史的T2D高心血管风险患者,可考虑使用利拉鲁肽。
- 利拉鲁肽未增加心衰住院风险,伴心衰史患者使用无需因心衰担忧住院风险增加。
局限性
- 心衰史分析为事后分析,非预设主要分析。
- NYHA IV级心衰患者被排除,结果不适用于该人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More data regarding effects of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes (T2D) and heart failure (HF) are required. OBJECTIVES: The purpose of this study was to investigate the effects of liraglutide on cardiovascular events and mortality in LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) participants, by HF history. METHODS: In the multinational, double-blind, randomized LEADER trial, 9,340 patients with T2D and high cardiovascular risk were assigned 1:1 to liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily) or placebo plus standard care, and followed for 3.5 to 5 years. New York Heart Association (NYHA) functional class IV HF was an exclusion criterion. The primary composite major adverse cardiovascular events outcome was time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Post hoc Cox regression analyses of outcomes by baseline HF history were conducted. RESULTS: At baseline, 18% of patients had a history of NYHA functional class I to III HF (liraglutide: n = 835 of 4,668; placebo: n = 832 of 4,672). Effects of liraglutide versus placebo on major adverse cardiovascular events were consistent in patients with (hazard ratio [HR]: 0.81 [95% confidence interval (CI): 0.65 to 1.02]) and without (HR: 0.88 [95% CI: 0.78 to 1.00]) a history of HF (p interaction = 0.53). In both subgroups, fewer deaths were observed with liraglutide (HR: 0.89 [95% CI: 0.70 to 1.14] with HF; HR: 0.83 [95% CI: 0.70 to 0.97] without HF; p interaction = 0.63) versus placebo. No increased risk of HF hospitalization was observed with liraglutide, regardless of HF history (HR: 0.98 [95% CI: 0.75 to 1.28] with HF; HR: 0.78 [95% CI: 0.61 to 1.00] without HF; p interaction = 0.22). Effects of liraglutide on the composite of HF hospitalization or cardiovascular death were consistent in patients with (HR: 0.92 [95% CI: 0.74 to 1.15]) and without (HR: 0.77 [95% CI: 0.65 to 0.91]) a history of HF (p interaction = 0.19). CONCLUSIONS: Based on these findings, liraglutide should be considered suitable for patients with T2D with or without a history of NYHA functional class I to III HF. (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER]; NCT01179048).
引用
- Marso SP, Baeres FMM, Bain SC, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020. PMID: 32164886. doi:10.1016/j.jacc.2019.12.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。